Different types of botulinum toxin in humans
Different types of botulinum toxin in humans
复制标题
DOI：
10.1002/mds.20010
复制
发表时间：
2004-03-01
影响因子：
8.6
通讯作者：
Montecucco, C
中科院分区：
文献类型：
--
作者：
Eleopra, R;Tugnoli, V;Montecucco, C
在人类中，肉毒杆菌神经毒素（BoNT）血清型A（BoNT/A）是有用的治疗工具，但是当证明与BoNT/A相关的特异性免疫抗性时，不同的BoNT血清型可能是有用的。将BoNT血清型F（BoNT/F）注射到人肌肉中，但其作用与BoNT/A相比较短，而BoNT血清型B（BoNT/B）仅在以非常高的剂量注射时才对人有效。BoNT血清型C（BoNT/C）具有与BoNT/A类似的一般作用特征。然而，这些不同的BoNT在人类之间的比较尚未报道。为了建立这些不同BoNT在人体中的一般概况以及在附近和未处理肌肉中的扩散，我们通过以双盲方式在小指展肌（ADM）中注射BoNT/A（BOTOX 15 MU）、BoNT/B（NeuroBloc 1500 MU）、BoNT/F（15 MU）、BoNT/C（15 MU）和盐水溶液（安慰剂），在12名健康志愿者中进行电生理学评价。分别于注射前及注射后2、4、6、8周，检测ADM、第四骨间背侧肌、第一骨间背侧肌和拇短展肌APB的复合肌肉动作电位（CMAP）波幅变化。与其他BoNT相比，我们检测到BoNT/F的早期恢复。在不同血清型之间未观察到本地或远处BoNT传播的显著差异。我们得出结论，在人类中，BoNT/B和BoNT/C具有与BoNT/A相似的一般特征，因此这些血清型可能是BoNT/A的替代疗法。BoNT/F可能是有用的，当只需要一个短时间的神经肌肉阻滞。(C)2004年，《运动障碍协会》。
In humans, botulinum neurotoxin (BoNT) serotype A (BoNT/A) is a useful therapeutic tool, but different BoNT serotypes may be useful when a specific immune resistance related to BoNT/A is proved. BoNT serotype F (BoNT/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas BoNT serotype B (BoNT/B) is effective in humans only if injected at very high doses. BoNT serotype C (BoNT/C) has a general profile of action similar to BoNT/A. Nevertheless, a comparison between these different BoNTs in human has not yet been reported. To establish the general profile of these different BoNTs in humans and the spread in near and untreated muscles we conducted an electrophysiological evaluation in 12 healthy volunteers by injecting BoNT/A (BOTOX 15MU), BoNT/B (NeuroBloc 1500MU), BoNT/F (15MU), BoNT/C (15MU) and a saline solution (placebo) in the abductor digiti minimi muscle (ADM) in a double-blind manner. The compound muscle action potential (CMAP) amplitude variation, before and at 2, 4, 6 and 8 weeks after the injections, was evaluated in the ADM, the fourth dorsal interosseus, the first dorsal interosseus and the abductor pollicis brevis APB. We detected an earlier recovery for BoNT/F when compared to the other BoNTs. No significant differences in the local or distant BoNT spread was observed among the different serotypes. We conclude that in humans, BoNT/B and BoNT/C have a general profile similar to BoNT/A and as such these serotypes could be alternative therapies to BoNT/A. BoNT/F might be useful when only a short duration of neuromuscular blockade is required. (C) 2004 Movement Disorder Society.